Curcumin eye study for people with retinal amyloid deposits
Part of Digestive system, Eyes & vision clinical trials.
This early-stage study tests whether curcumin (a natural plant compound) can affect eye changes in people who have amyloid deposits in the retina. It aims to see if the treatment is safe and possibly helpful for vision-related outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 89 years old.
- You have amyloid (Aβ) deposits in the retina (the eye exam may be repeated after you consent).
- You do not have known liver or kidney disease (based on what you report).
- You have not used turmeric or curcumin products in the 2 weeks before starting the study.
- You have not taken systemic antibiotics in the month before starting the study.
- You do not have an allergy to black pepper, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding oral curcumin (a natural supplement) to standard eye injections (bevacizumab) improves treatment for diabetic macular edema, a swelling in the back of the eye that can affect vision.
This study tests how a single dose of a new curcumin (turmeric-based) product is absorbed by the body in healthy people who have not eaten. It helps researchers understand if the product works as expected before larger studies.
This study uses detailed eye imaging to look for patterns that may go along with conditions like Alzheimer’s disease, memory problems, multiple sclerosis, or eye/vascular issues. It may help researchers better understand how eye findings relate to health and disease.
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
This study uses a special dye and imaging to see if certain immune cells (dendritic cells) travel to the retina. It aims to understand how the immune system might play a role in dry age-related macular degeneration, mild cognitive impairment due to Alzheimer's, or early Alzheimer's disease.
Hear when a new Bioavailability trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.